CAR T cell therapy has been employed with great success in childhood haematological malignancies targeting CD19.8–10 However, the success of CAR T cell therapy in adult high-grade glioma has been disappointing, in part due to the immunosuppressive nature of gliomas, but mostly due to the heterogeneity of CNS tumors and the relative paucity of authentic tumor-specific antigens to enable sufficient tumor coverage.5,11. This evidence concerns the gene CD19 and glioma.